Fidelity National Information Services Inc. (FIS)

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Fidelity National Information Services Inc. (FIS) Financials Nov 20, 2014, 6:07 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Fidelity National Information Services Inc.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 3.77B 5.27B 5.75B 5.81B 6.07B
Cost of Goods Sold (COGS) incl. D&A 2.8B 3.64B 4B 3.95B 4.09B
COGS excluding D&A 2.37B 3.01B 3.36B 3.31B 3.47B
Depreciation & Amortization Expense 434M 630.1M 637.2M 632.8M 614.6M
Depreciation 81.3M 123M 110.7M 117.8M 119M
Amortization of Intangibles 303.3M 447.8M 460.6M 442M 429M
Gross Income 968.9M 1.63B 1.75B 1.86B 1.99B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 554.1M 675.8M 658.8M 781.5M 782.5M
Research & Development - - - - -
Other SG&A 554.1M 675.8M 658.8M 781.5M 782.5M
Other Operating Expense 0 0 0 0 0
Unusual Expense 226.3M 188M 46.8M 0 199.6M
EBIT after Unusual Expense (226.3M) (188M) (46.8M) 0 (199.6M)
Non Operating Income/Expense 8.7M (53M) (84.4M) (33M) 4.7M
Non-Operating Interest Income 3.4M 6.4M 6M 8.6M 10.4M
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 44.6M 105.1M 219.4M 223.6M 193.1M
Gross Interest Expense 50.9M 105.1M 219.4M 223.6M 193.1M
Interest Capitalized 6.3M 0 0 0 0
Pretax Income 156M 616.3M 744.3M 831.2M 825M
Income Tax 52.1M 215.3M 239M 270.9M 309.2M
Income Tax - Current Domestic 106M 245M 185M 221.8M 259.4M
Income Tax - Current Foreign 6.3M 26M 52.8M 34M 49.6M
Income Tax - Deferred Domestic (58M) 10.3M 28.2M 15.3M (900,000)
Income Tax - Deferred Foreign (2.2M) (66M) (27M) (200,000) 1.1M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 103.9M 401M 505.3M 560.3M 515.8M
Minority Interest Expense 2.6M (46.6M) 11.5M 19.9M 24.6M
Net Income 101.3M 447.6M 493.8M 540.4M 491.2M
Extraordinaries & Discontinued Operations 4.6M (43.1M) (24.2M) (79.2M) 1.9M
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 4.6M (43.1M) (24.2M) (79.2M) 1.9M
Net Income After Extraordinaries 105.9M 404.5M 469.6M 461.2M 493.1M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 101.3M 447.6M 493.8M 540.4M 491.2M
EPS (Basic) 0.45 1.17 1.56 1.58 1.70
Basic Shares Outstanding 236.4M 345.1M 300.6M 291.8M 289.7M
EPS (Diluted) 0.44 1.15 1.53 1.55 1.68
Diluted Shares Outstanding 239.4M 352M 307M 297.5M 294.2M
EBITDA 848.8M 1.59B 1.73B 1.71B 1.82B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading